Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes

Conclusion: The 64Cu-labeled PSMA ligands are promising agents to target PSMA and visualize PSMA-positive tumor lesions as shown in preclinical evaluation by small-animal PET studies, organ distribution, and a patient application. Most importantly, the images obtained at 20 h enabled delineation of unclear lesions, showing that the compounds fulfill the prerequisite for dosimetry in the course of therapy planning with 67Cu. Thus, we suggest clinical use of copper-labeled CA003 for diagnostics and radiotherapy of prostate cancer.

Source: Journal of Nuclear Medicine - January 1, 2020 Category: Nuclear Medicine Authors: Carlos dos Santos, J., Beijer, B., Bauder-Wust, U., Schafer, M., Leotta, K., Eder, M., Benešova, M., Kleist, C., Giesel, F., Kratochwil, C., Kopka, K., Haberkorn, U., Mier, W. Tags: Basic Source Type: research